8th Annual Bio Investor Forum

RNS Number : 3723Z

Immupharma PLC

21 September 2009

 



For Immediate Release

21 September 2009

ImmuPharma PLC

IMMUPHARMA TO PRESENT AT 8TH ANNUAL BIO INVESTOR FORUM

ImmuPharma PLC (LSE:IMM), the drug discovery and development group announces that Dimitri Dimitriou, Chief Executive Officer will be presenting at the 2009 BIO Investor Forum. Hosted by the Biotechnology Industry Organisation (BIO), the 8th Annual BIO Investor Forum will take place on October 28-29 at the Palace Hotel in San Francisco, California. 

- Ends -

For further information please contact: 

ImmuPharma PLC:	[phone]
Dimitri Dimitriou, Chief Executive Officer
Buchanan Communications:	[phone]
Lisa Baderoon

Notes to Editors

About ImmuPharma PLC

ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. 

Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009

The company also has a strong proprietary and collaborative drug development pipeline.

About The Bio Investor Forum 

The 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year's BIO Investor Forum will feature more than 110 presentations by private and publicly traded companies, venture philanthropy organizations, and patient advocacy groups; as well as Therapeutic Workshops™ and Business Roundtables with distinguished clinicians, investigators, and investors. Experts hand-selected to speak at this conference will focus on current biotechnology pipeline innovation, and the latest trends in clinical strategy, capital access and creative funding techniques. The Eighth Annual BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors, and research analysts as well as business development executives from leading global pharmaceutical and mature biotechnology companies. 

 

END

 

 

NRASEDSAFSUSEIU